WOODCLIFF LAKE, N.J., June 23, 2014 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Barry Lederman to the position of Vice President and Chief Financial Officer (CFO). In this role, Mr. Lederman will have full oversight and responsibility for leading Eisai's financial operations in the Americas Region. He also will serve as a member of the company's Executive Committee.
Mr. Lederman has extensive financial and operational experience, having led the financial teams of several public and private companies. Prior to joining Eisai, he served as CFO at Wedgewood Pharmacy, Nycomed US Inc., and Qualitrol Company LLC (an independent subsidiary of Danaher Corporation). He also spent 10 years at Hoffmann-La Roche Inc. in positions of increasing responsibility within Finance, culminating in his appointment as Senior Vice President Head of Business Analysis and Controlling at Roche Centralized Diagnostics, headquartered in Mannheim, Germany. Over his 20-year career in finance, Mr. Lederman has been recognized for achievements in revenue and profit improvement, business development, acquisitions and integrations, business modeling, and building and leading top performing teams.
"We are pleased to welcome Barry to the executive team at Eisai," said Shaji Procida, President and Chief Operating Officer of Eisai Inc. "Barry's financial expertise and business leadership will help us ensure the continued financial well-being of our company as Eisai enters the next phase of its renewal and growth."
Mr. Lederman holds a Master of Business Administration with a dual concentration in Finance and Operations Management from the William E. Simon Graduate School of Business Administration at the University of Rochester and a Bachelor of Science in Electrical Engineering from the University of Rochester. In addition, he is a certified public accountant licensed in New Jersey and New York and gained his accounting experience at PricewaterhouseCoopers LLP.
Mr. Lederman was recently voted in as a board member with the Northern New Jersey Council of the Boy Scouts of America. He actively supports his local Boy Scout Troop where he is an Assistant Scoutmaster. Mr. Lederman has been recognized twice for his commitment to volunteer service, earning the President's Volunteer Service Award in 2008 (Gold level 500 or more hours of service) and in 2007 (Bronze level 100 or more hours of service) for his efforts to serve his community. In addition, he achieved the rank of Eagle Scout.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.
Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.
Logo - http://photos.prnewswire.com/prnh/20120413/MM87168LOGO
SOURCE Eisai Inc.